TPST-1120, a first-in-class oral inhibitor of peroxisome proliferator activated receptor alpha (PPAR-alpha), appeared to be well tolerated as both monotherapy and in combination with nivolumab (Opdivo), in patients with PD-1 inhibitor-refractory cancers, including renal cell carcinoma (RCC).1
